The St. Joe's Experience ealth & wellness Little Hearts Easy, painless test can detect defects. W St. Joe's Lung Cancer Program Offers the Latest Diagnostics, Treatment Although lung cancer remains the second highest cause of cancer death in men and women combined, recent treatment breakthroughs provide ways to earlier diagnose and better treat the disease. A diagnosis of lung cancer no longer has to be a death sentence. St. Joseph Mercy Oakland has taken deliberate steps to expand our Lung Cancer Program to offer the latest in diagnostics, treatment and clinical trials for patients with, or suspected to have, lung cancer. Here's why you should seek out St. Joe's for lung cancer diagnosis and treatment. We now offer: • A quicker path to diagnosis and treatment with twice monthly multidisciplinary Lung Tumor Board meetings attended by a team that includes nationally recognized experts in Radiation Oncology and Thoracic Surgery, along with specialists in Pulmonary Medicine, Medical Oncology, Pathology, Radiology and others. Working together, the team develops a personalized cancer treatment plan for each patient designed to deliver the best outcomes. • A lung cancer nurse navigator who facilitates care for each patient. She provides patient education, coordinates appointments and provides additional emotional and resource support throughout each patient's treatment journey. • Our nationally recognized specialists are Thoracic Surgeon M. Salik Jahania, MD, and a team of 21st Century Oncology radiation oncologists led by Larry Kestin, MD, who have dedicated SJMO-affiliated lung cancer practices and are skilled and experienced in the latest cutting-edge diagnostic and treatment technology. • Superdimension Navigational Bronchoscopy System, Endobronchial Ultrasound (EBUS) and Low-Dose Lung CT screening for the latest in detection, diagnosis and staging, along with da Vinci robotic-assisted surgery. • A Surgical Pavilion with modern surgical suites that offers the most up-to-date technological advances in the area. • Access to nearly 150 clinical trials through our Community Clinical Oncology Program (CCOP), the same trials accessed by the Mayo Clinic. This means patients can receive cutting-edge treatment while remaining right in our community. • Expertise in Pain and Palliative Care. St. Joe's program was one of the first in the nation and first in the state to achieve accreditation by The Joint Commission. • Access to educational information, a financial navigator, clinical nutrition support and integrated therapy in our new Cancer Resource and Support Center, which will open in April within the Alice Gustafson Center on the hospital campus. • A renovated and expanded Cancer Center, also in the Alice Gustafson Center, that offers an environment of patient comfort and dignity in both the physician office and the new infusion center. For more information on St. Joe's expanded Lung Cancer Program, call Patti Moore, Lung Nurse Navigator, at 248-858-3471. I also encourage you to attend an open house to view the renovated Cancer Center and the new Cancer Resource and Support Center in the Alice Gustafson Center on campus, 44405 Woodward Ave., Pontiac, on Saturday, April 13, from 9:30 a.m. to 1 p.m. When you're looking for the latest, comprehensive and compassionate lung cancer care, come to St. Joseph Mercy Oakland, where our clinical outcomes speak for themselves. By Jack Weiner, President and CEO St. Joseph Mercy Oakland DISCOVER REMARKABLE ADVERTISEMENT 56 ..arch 28 • 2013 hen you're expecting a bundle of joy, you run the gamut of emotions from excited to scared. But by including a simple screen- ing for critical congenital heart defects in all newborn exams at Beaumont, parents can breathe a small sigh of relief. "All babies who are born at any of the Beaumont hospitals and are at least 35 weeks gestation will have a pulse oximetry screening. It's a simple test for newborns that can help find a critical congenital heart defect:' says Judith Klarr, M.D., neo- natologist, Beaumont Children's Hospital. "Since June, we have screened about 3,000 babies at Beaumont, Royal Oak:' Prior to discharge, within 48 hours, the screening is done. A sensor is placed on the baby's right hand and foot to see how much oxygen is in the blood. The screen- ing is a painless, non-invasive procedure that takes only one minute to complete. When a baby is born with a critical congenital heart defect, or CCHD, their tiny heart or major blood vessels did not form properly. It's called "critical" because it requires surgery or a catheter-based treatment. "These are the babies who would have gone home and died without explanation:' explains Klarr. Klarr adds, "Until recently, research was not available indicating the correla- tion with low oxygen and heart defects. Now we know this test can save lives and improve surgical outcomes for our tiny patients:' In addition to screening all newborns, Beaumont Children's Hospital also pro- vides the test to babies who are less than seven days old who are transferred or admitted from hospitals that don't require the screening. "When test results show low levels of oxygen in the blood, which can be a sign of a CCHD, it means that more testing is needed:' says Klarr. "We have the ability to diagnose and stabilize them when it is most critical:' ❑ Johanna's Legacy Finding new treatments for ovarian cancer. T he passage of 12 years can pro- vide a degree of healing from the intense grief that follows losing a loved one in the prime of life to cancer. Working to make sure that loved one did not die in vain can help the healing pro- cess, too. That's why the Michigan-based Silver Family Foundation for Ovarian Cancer Research chose Caitlin Stashwick, M.D., for Johanna its Johanna's Fund Silver Gordon Ovarian Cancer Research Grant. Established to pro- mote research to com- bat newly diagnosed and recurrent ovarian cancer, the fund is named for Johanna Silver Gordon, a Sheryl Silver lifelong Temple Israel member and Southfield-Lathrup High School teacher who lost her life to ovarian cancer after a determined, 31/2-year fight for survival. Sheryl Silver of Birmingham, founder of the foundation and Johanna's younger sister, said, "I'm thrilled that Dr. Stashwick's research is focused on creat- ing new and better treatments for recur- rent and late-stage ovarian cancer. It was heartbreaking to watch my sister Johanna lose her life — then several other friends lose theirs — when they ran out of effec- tive drugs and treatments. Although research to create a better method of detecting ovarian cancer at its earliest, most survivable stage is crucial and has been ongoing for over a decade:' noted Silver, "our board believes research directed at treatments to prolong and/ or save the lives of women already diag- nosed with late-stage ovarian cancer must also be a high priority. The vast major- ity of Americans newly diagnosed with ovarian cancer each year are diagnosed at these later stages:' Stashwick's research involves investi- gating immune-based therapy for treat- ment of newly diagnosed and recurrent ovarian cancer. A gynecologic oncology fellow with University of Pennsylvania's Perelman School of Medicine, she was selected for the Johanna's Fund grant following a competitive research grant review process by the Foundation for Women's Cancer, the educational foun- dation of the Society of Gynecologic Oncology (SGO). ❑